GLP-1 weight-loss plateaus: what a pause on the scale can mean

First describe what has changed

“My weight has stalled” can describe several experiences: three similar readings, a slower downward trend, or months of little change after an earlier reduction. Tell the care team which one you mean. Include the dates and the longer history rather than sending only the latest number.

For example, imagine someone comparing three weekly readings that are close together after several months of weight loss. Those readings are a reason to ask how to interpret the trend; they do not show that the medicine has stopped having an effect. This is an illustrative situation, not a diagnosis or a rule about how long to wait.

Agree with the clinician on a reasonable way to monitor weight and other relevant outcomes. The aim is a record that supports a decision, without making every individual reading a test of success.

The early rate of loss is not a permanent pace

Mayo Clinic’s explanation of weight-loss plateaus describes two reasons the trajectory can change: early losses can include water associated with stored glycogen, and the body may expend less energy after weight reduction. The same routine can therefore produce a different weight trend later.

These mechanisms provide background; they cannot identify the cause of a particular person’s pause from a message or a chart. A review should also consider the treatment actually taken, changes in routine, other medicines and symptoms.

Avoid responding with increasingly restrictive eating or an exhausting exercise target copied from a stranger’s post. A clinician or registered dietitian can help assess whether the current eating and activity plan remains adequate, realistic and appropriate for your health.

A study’s definition is more specific than “the scale stopped”

A 2025 exploratory analysis of SURMOUNT-1 and SURMOUNT-4 examined plateau timing during tirzepatide treatment. In SURMOUNT-1, its definition required less than 5% weight change during a 12-week interval and during each later interval. It did not require weight to remain exactly unchanged.

The analysis selected participants who had taken at least 75% of assigned doses, lost at least 5% by the study endpoint and met additional stable-dose and measurement requirements. The trials enrolled adults without diabetes. Most participants in the analyzed SURMOUNT-1 groups met the study’s plateau definition by week 72.

That selected group cannot tell every new patient when a plateau will occur, or explain people who did not achieve the required initial loss. The analysis was not a trial of patient-directed dose changes after a brief stall. Several authors were employees of the manufacturer. Read its methods and limitations alongside the finding.

Review the benefit already achieved and the goal ahead

NIDDK’s medication overview explains that treatment duration depends on benefit and side effects, including whether medicine helps maintain lost weight. A flat trend after a useful reduction raises a different question from little benefit throughout treatment.

Discuss the health outcomes that led to the prescription and whether they have changed. Depending on your medical situation, the clinician may consider blood pressure, blood sugar, physical function or other agreed goals along with weight. The relevant measures should come from your care plan.

Ask what would justify continuing, reviewing the approach or considering another treatment. A published study average and another person’s goal weight cannot make that decision for you. Contact the care team when you are concerned; a research interval is not a required waiting period for care.

Bring a short record that makes the next conversation useful

HHS recommends preparing medicines, measurements and questions for a telehealth visit. For a weight-trend review, these details can help the clinician see what happened together. Send personal health information through the service’s clinical channel.

Use the record to ask one clear question: “How should we assess my current response, and what follow-up do you recommend?” It is more useful than requesting a particular increase before the clinician has reviewed the situation.

• The exact medication and formulation, your prescribed instructions, and when treatment began.
• Dated weight measurements and when the pace appeared to change.
• Any missed treatment, supply interruption or uncertainty about the instructions.
• Side effects, difficulty eating or drinking, and changes in other medicines or routine.
• The goals you agreed on and the specific question you want answered.

How this question connects to CoreAge Rx follow-up

The CoreAge Rx product overview lists compounded injectable semaglutide and tirzepatide. The plateau analysis above studied trial participants receiving tirzepatide; it does not establish a response timetable for CoreAge Rx patients or its compounded products.

CoreAge Rx describes asynchronous physician messaging through its portal, with responses typically taking one to three business days. Its refill instructions include a check-in and provider review. Use those routes to ask how the team will assess a slowing trend, and confirm whether a concern needs an earlier clinical conversation.

Our guide to ongoing GLP-1 support explains how to evaluate those arrangements before enrolling. The CoreAge Rx review provides service background; neither an advertised support channel nor a study result guarantees an individual outcome.

Keep changes to the prescription within clinical care

FDA reports dosing problems with compounded semaglutide and tirzepatide, including excessive amounts, more frequent administration and overly rapid increases. A disappointing scale reading is not a basis for improvising those changes or combining weight-management products.

If a clinician recommends a switch, obtain instructions for the actual products involved. Ingredient names and milligram numbers do not establish a self-directed conversion between semaglutide and tirzepatide.

FDA also explains that compounded GLP-1 medicines are not approved and should be used only when an approved drug cannot meet a patient’s medical needs. Ask about that basis when evaluating a proposed compounded prescription.

A plateau question can usually be discussed through ordinary follow-up, but severe or worsening symptoms need timely medical assessment. Do not wait for a routine portal reply when you need urgent care.

Common questions

Keep researching

• Compare the support behind an online GLP-1 program
• Research the CoreAge Rx service
• Browse GLP-1 Planet’s treatment guides